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http://dx.doi.org/10.1016/j.ccr.2014.07.026SUMMARYEpstein-Barr virus-induced lymphoproliferative disease (EBV-LPD) after transplantation remains a serious
and life-threatening complication. Herein we showed that the aminobisphosphonate pamidronate-expanded
human Vg9Vd2-T cells efficiently killed EBV-transformed autologous lymphoblastoid B cell lines (EBV-LCL)
through g/d-TCR and NKG2D receptor triggering and Fas and TRAIL engagement. By inoculation of
EBV-LCL in Rag2/gc/ mice and humanized mice, we established lethal EBV-LPD with characteristics
close to those of the human disease. Adoptive transfer of pamidronate-expanded Vg9Vd2-T cells alone effec-
tively prevented EBV-LPD in Rag2/gc/ mice and induced EBV-LPD regression in EBV+ tumor-bearing
Rag2/gc/ mice. Pamidronate treatment inhibited EBV-LPD development in humanized mice through
selective activation and expansion of Vg9Vd2-T cells. This study provides proof-of-principle for a therapeutic
approach using pamidronate to control EBV-LPD through Vg9Vd2-T cell targeting.INTRODUCTION
Epstein-Barr virus (EBV) is a herpesvirus that latently infects
human B cells in most individuals by adulthood. Persistent
EBV infection is generally subclinical in immunocompetent hosts
(Cohen, 2000). However, immunocompromised patients are at
high risk of developing EBV-induced B cell lymphoproliferative
disorders (EBV-LPD) with significant morbidity and mortalitySignificance
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Rooney et al., 1995). However, its application for the treatment
of EBV-LPD is limited by the difficulties in generating enough
numbers of EBV-specific CTL in vitro and the lack of in vivo
expansion of infused CTL in patients with bulky disease (Leen
et al., 2007; Louis et al., 2009). Antibody-mediated targeting
EBV-infected B cells has unwanted side effects because anti-
CD20 antibody also depletes normal B cells causing prolonged
hypogammaglobulinemia, and chemotherapy has unwanted
off-target toxicity and also causes general immunosuppression
(Leen et al., 2007). Thus, there is an urgent need for developing
better strategies to control EBV-LPD.
gd-T cells are considered as the innate-like T lymphocytes
with natural killer (NK) cell characteristics (Born et al., 2006;
Carding and Egan, 2002). Various innate signals, either alone
or in combination with ligand recognition via the T-cell receptor,
induce gd-T cells to display innate-like immune functions
(Bonneville and Scotet, 2006; Born et al., 2006; Zheng et al.,
2013a). gd-T cells make up 1%–10% of T lymphocytes in the
blood and peripheral organs in adult humans. Most gd-T cells
in the peripheral blood and lymphoid organs of healthy human
adults are Vg9Vd2-T cells. Vg9Vd2-T cells can be specifically
activated in an HLA-unrestricted manner by small nonpeptidic
phosphoantigens, which are metabolites of isoprenoid bio-
synthesis pathways (Beetz et al., 2008). Isopentenyl pyrophos-
phate (IPP), an intermediate produced through the mevalonate
pathway, was found to selectively activate and expand human
Vg9Vd2-T cells in vitro and in vivo (Alexander et al., 2008; Puan
et al., 2007). Pharmacological compounds, such as the aminobi-
sphosphonate pamidronate commonly used for the treatment
of osteoporosis, can induce intracellular accumulation of IPP,
leading to activation and expansion of human Vg9Vd2-T cells
(Bonneville and Scotet, 2006). Human Vg9Vd2-T cells can exert
broad antiviral and antitumor activities in vitro and in humanized
mice in vivo (Fournie´ et al., 2013; Qin et al., 2011, 2012; Tu et al.,
2011). However, whether these cells have similar effects on EBV
and EBV-LPD remains unknown.
Recently we established humanized mice with human periph-
eral blood mononuclear cells (huPBMC). These mice contain
functional human T and B cells, including a similar percentage
of Vg9Vd2-T cells in peripheral blood as seen in human
(Tu et al., 2011; Zheng et al., 2013b). In this study, we investi-
gated the effect of pamidronate-expanded human Vg9Vd2-T
cells on the growth of EBV-transformed autologous lymphoblas-
toid B cell lines (EBV-LCL) in vitro and in immunodeficient
Rag2/gc/mice, and further determined the role of pamidro-
nate in the control of EBV-LPD in humanized mice.
RESULTS
Vg9Vd2-T Cells Kill EBV-LCL In Vitro
EBV-LCL showed enhanced expression of stress-inducible ma-
jor histocompatibility complex class I-related proteins A and B
(MICA/B), Fas, and tumor necrosis factor-related apoptosis-
inducing ligand (TRAIL) receptor 2 (DR5) expression when
compared to their normal autogolous B cells (Figure 1A).
In contrast, both normal B cells and EBV-LCL had little or no
Fas ligand (FasL) and TRAIL receptor 1 (DR4) expression on
the cell surface (Figure 1A). Consistent with our previous reports566 Cancer Cell 26, 565–576, October 13, 2014 ª2014 Elsevier Inc.(Li et al., 2013; Tu et al., 2011), pamidronate induced selective
activation and expansion of Vg9Vd2-T cells, and upregulation
of the surface expressions of CD69, NKG2D, FasL, TRAIL, and
intracellular cytolytic granules, perforin and granzyme B, in
Vg9Vd2-T cells (Figures S1A–S1D available online). In contrast,
EBV-LCL alone could not efficiently expand Vg9Vd2-T cells
from EBV-seropositive donors (Figures S1E and S1F).
Pamidronate-expanded Vg9Vd2-T cells were purified by pos-
itive or negative selection with anti-TCRg/dMicroBead or TCRg/
d+ T cell isolation kit, and then co-cultured with autologous EBV-
LCL. As shown in Figure 1B, pamidronate-expanded Vg9Vd2-T
cells sorted through negative selection only had minor cytotoxic
activity against EBV-LCL, whereas pamidronate-expanded
Vg9Vd2-T cells sorted through positive selection had significant
higher cytotoxic activity against EBV-LCL. In addition, Vg9Vd2-T
cells sorted through positive selection had higher CD69, Fas,
FasL, TRAIL, and granzyme B expressions than those sorted
through negative selection (Figure S1G). These results indicated
that recent g/d-T cell receptor (TCR) engagement enhanced their
activation and cytotoxicity against EBV-LCL.
Pamidronate-expanded Vg9Vd2-T cells sorted through posi-
tive selection displayed potent cytotoxicity against EBV-LCL
in a dose-dependent manner, but showed limited if any killing
activity against normal B cells (Figure 1C). This cytotoxicity
required cell-cell direct contact, as indicated by Transwell exper-
iments (Figure 1D). The immobilized recombinant MICA/B
enhanced Vg9Vd2-T cell activation, especially for the cells
sorted through positive selection, in terms of the expressions
of CD69, NKG2D, Fas, FasL, TRAIL, perforin, or granzymeB (Fig-
ure S1G). The significant granule exocytosis, as evidenced by
the increase of surface expression of CD107a, was also detected
in Vg9Vd2-T cells upon the immobilized MICA/B stimulation
(Figure 1E). In parallel with granule exocytosis, the immobilized
MICA/B significantly enhanced the cytotoxic activity of
Vg9Vd2-T cells against EBV-LCL (Figure 1F). Indeed, the levels
of the granule exocytosis and cytotoxicity of Vg9Vd2-T cells
sorted through positive selection were much higher than that in
cells sorted through negative selection upon the immobilized
MICA/B stimulation (Figures 1E and 1F). These data suggest
MICA/B expressed EBV-LCL can enhance the activation and
cytotoxic activity of Vg9Vd2-T cells especially those sorted
through positive selection. Therefore, pamidronate-expanded
Vg9Vd2-T cells purified with g/d-TCR positive selection were
used for subsequent experiments.
Blockade of NKG2D, FasL, and TRAIL using appropriate
neutralizing antibodies significantly inhibited the cytolytic activ-
ities of Vg9Vd2-T cells against EBV-LCL (Figure 1G). To confirm
the involvement of cytolytic granule release in the killing of EBV-
LCL by Vg9Vd2-T cells, the perforin-specific inhibitor concana-
mycin A (CMA) and granzyme B inactivator Bcl-2 were used.
As shown in Figure 1G, cytolytic activity of Vg9Vd2-T cells
against EBV-LCLwas strongly inhibited after CMA or Bcl-2 treat-
ment. These results indicate that the cytotoxicity of Vg9Vd2-T
cells against EBV-LCL depends on NKG2D activation, and is
mediated by Fas-FasL, TRAIL-DR5, and perforin-granzyme B
pathways. In addition, pamidronate alone did not show any cyto-
toxic activities against EBV-LCL (Figures S1H and S1I), but it
could enhance the expression of EBV-LCL recognition receptors
and cytotoxic molecules in Vg9Vd2-T cells (Figure S1J). Taken
Figure 1. Vg9Vd2-T Cells Kill EBV-LCL In Vitro
(A) Phenotypes of EBV-LCL and autologous normal human B cells. The white histograms represent MICA/B, Fas, FasL DR4 and DR5, and the gray histograms
represent isotype controls. (B, E, and F) Pamidronate (PAM)-expanded Vg9Vd2T cells were purified by positive selection (P-gd-T) or negative selection (N-gd-T)
with anti-TCRg/d MicroBead or TCRg/d+ T cell isolation kit, and then cultured with the autologous EBV-LCLs at different ratios for 4 hr. (C, D, and G) PAM-
expanded Vg9Vd2T cells purified by positive selection were cocultured with autologous EBV-LCL or normal B cells at different E:T ratios (C) or an E:T ratio of 10:1
(D and G) for 4–6 hr. (D) The Vg9Vd2T cells were directly cocultured with or physically separated from autologous EBV-LCLs for 6 hr by using a transwell system.
(E and F) P-gd-T or N-gd-T cells were pretreated with or without immobilizedMICA/B for 6 hr, and then cocultured with autologous EBV-LCL at an E:T ratio of 10:1
for 4–6 hr. The percentages of dead cells amongwhole target cells (CD3 population) identified as CD3PI+ (B–D and F) and the surface expression of CD107a on
Vg9Vd2T cells (E) are shown. (G) The perforin inhibitor CMA, granzyme B inactivator Bcl-2, anti-NKG2D (aNKG2D), anti-TRAIL (aTRAIL), and anti-FasL (aFasL)
blocking antibodies, or their relevant isotype control (mouse IgG1, mIgG1) were used in coculture of EBV-LCL and their autologous PAM-expanded Vg9Vd2T
cells. The cytotoxicity was shown as the percentage of inhibition relative to those without any treatment. All the data shown as mean ± SEM are representative of
four independent experiments. *p < 0.05. See also Figure S1.
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Vg9Vd2-T cells can efficiently kill EBV-LCL.
Vg9Vd2-T Cells Prevent EBV-LPD in Rag2–/–gc–/– Mice
Human B cells infected with the EGFP-tagged EBV were used to
establish EGFP+ EBV-LCL to monitor the growth of EBV-LCLs
in vivo. The EBV-LPD model was further established in the
Rag2/gc/ immunodeficient mice after subcutaneous (s.c.)
inoculation of EGFP-expressing EBV-LCL (0.1 3 106/mouse;
Figure 2A; Lacerda et al., 1996). To determine whether human
Vg9Vd2-T cells could prevent EBV-LPD in vivo, highly purified
(>97%) pamidronate-expanded autologous Vg9Vd2-T cells
(103 106 cells/mouse) were adoptively transferred intravenously
(i.v.) into Rag2/gc/mice at days 0, 7, 14, and 21 after EGFP-
expressing EBV-LCL inoculation (Figure 2A). PBS-treated mice
were used as controls.
After inoculation with EBV-LCL, EBV-LPD developed in all
control mice. The rapid growth of EBV-LCLwas detected subcu-Ctaneously in PBS-treated mice by in vivo imaging after inocula-
tion with EBV-LCL (Figure 2B), and subcutaneous solid tumors
developed in all control mice (Figures 2B and C). Histologically,
these tumors were immunoblastic lymphomas and derived
from human B cells as evidenced by positive staining for human
CD20 (Figure 2D). The tumor cells had high expression levels of
EBV latent membrane protein 1 (LMP1) and small EBV-encoded
RNAs type 1/2 (EBER-1/2) expressions (Figure 2D). Furthermore,
tumor metastases in liver, kidney, and lung were evidenced by
histological and immunophenotypic analysis for CD20, LPM1,
and EBER-1/2 expression (Figure 2E). As a result, 9 of 11
(82%) PBS-treatedmice diedwithin 60 days after EBV-LCL inoc-
ulation (Figure 2F).
Adoptive transfer of Vg9Vd2-T cells significantly enhanced
survival of EBV-LCL-grafted immunodeficient mice (Figure 2F).
Indeed only 1 of 10 mice with adoptively transferred Vg9Vd2-T
cells died during the 100 day-observation period (Figure 2F),
and subcutaneous solid tumors developed in only 2 of 10 miceancer Cell 26, 565–576, October 13, 2014 ª2014 Elsevier Inc. 567
Figure 2. Vg9Vd2-T Cells Prevent EBV-LPD in Rag2–/–gc–/– Mice
(A) Protocol of establishment of EBV-LPD mice model and evaluation of the antitumor activity of Vg9Vd2-T cells in vivo. Rag2/gc/mice were inoculated s.c.
with EGFP-expressing EBV-LCL. The PAM-expanded autologous Vg9Vd2-T cells were adoptively transferred i.v. into Rag2/gc/mice after inoculation with
EBV-LCLs at days 0, 7, 14, and 21. The mice treated with an equivalent volume of PBS were the control group. The subcutaneous tumors were monitored with
in vivo imagine system at indicated time.
(B) Whole body fluorescence images in mice treated with PAM-expanded Vg9Vd2-T cells or PBS (n = 5 per group) are shown (X = death).
(legend continued on next page)
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transfer of Vg9Vd2-T cells, these cells could persist for up to
98 days in the peripheral blood in the EBV-LCL-grafted mice
(Figure S2). Histological and immunophenotypic analysis of
CD20, LPM1, and EBER-1/2 expression showed no evidence
of tumor metastases in liver, kidney, and lung at autopsy
in Vg9Vd2-T cells-treated mice after 100 days after EBV-LCL
inoculation except in one mouse that died at day 60 (Figure 2E).
Importantly, the volume of subcutaneous tumors in mice
receiving Vg9Vd2-T cells was significantly reduced when
compared to that in PBS-treated mice (Figure 2H). Histological
and immunophenotypic analysis of the residual tumors further
showed that the B cell lymphomas had fewer Ki67-positive cells
in mice receiving Vg9Vd2-T cells than that in PBS-treated
mice (Figure 2I), indicating the residual tumor cells in Vg9Vd2-T
cell-treated mice had lower proliferative capacity than that in
PBS-treated mice. These data demonstrated that pamidro-
nate-expanded Vg9Vd2-T cells alone can effectively prevent
EBV-LPD in Rag2/gc/ mice.
Vg9Vd2-T Cells Induce the Regression of EBV-LPD in
Tumor-Bearing Rag2–/–gc–/– Mice
To determine whether Vg9Vd2 T cells had therapeutic effect
on EBV-LPD in mice, EGFP-expressing EBV-LCL (0.1 3 106/
mouse) were inoculated into Rag2/gc/mice s.c. (Figure 3A).
Twenty-one days later, large subcutaneous tumors (medium sur-
face area, 137 mm2) had developed in all the mice as detected
with in vivo imaging (Figures 3B and 3C). Then half of these tu-
mor-bearing mice were adoptively transferred with highly puri-
fied pamidronate-expanded autologous Vg9Vd2-T cells (10 3
106 cells/mouse) i.v. at days 21, 28, 35, and 42, and another
half of these tumor-bearing mice were treated with PBS as the
control (Figure 3A). PBS-treated mice had subcutaneous tumor
with progressive growth and extension to the abdominal cavity,
liver, and kidney (data not shown), ultimately causing death
within 43 days after EBV-LCL inoculation (Figures 3C–3E). In
contrast, Vg9Vd2-T cell treatment constrained tumor growth,
and only one of six mice died at day 107 after EBV-LCL inocula-
tion (Figures 3C and 3D). The other five of six Vg9Vd2-T cell-
treated mice were still alive more than 170 days after EBV-LCL
inoculation (Figure 3D). In addition, Vg9Vd2-T cell treatment
significantly reduced the volume of the subcutaneous tumors
in these five mice (Figures 3C and 3E). At day 170, the surviving
five mice were killed and full necropsies performed, and no evi-
dence of tumor metastasis in other organs was found in these
surviving mice. In contrast to the intact B cell lymphomas with
numerous Ki67-positive cells in PBS-treated mice, histological
and immunophenotypic analysis showed large areas of necrosis
with calcification and interlaced fibrous tissue and scarce
Ki67-positive cells in some residual tumors from Vg9Vd2-T
cell-treated mice (Figure 3F). These results indicated that pa-(C) Typical appearance of subcutaneous tumor in Rag2/gc/ mice from PBS
(D, E, and I) Representative histological analysis, immunohistological stainings fo
fixed paraffin-embedded sections from a tumor (D and I) and liver, kidney and lu
represents 100 mm.
(F–H) After treatmentwith PAM-expanded Vg9Vd2-T cells (n = 10) or PBS (n = 11), t
(H) were measured. *p < 0.05.
See also Figure S2.
Cmidronate-expanded Vg9Vd2-T cells can induce the regression
of EBV-LPD in Rag2/gc/ mice.
Vg9Vd2-T Cells Preferentially Home to Subcutaneous
Tumor Sites
To evaluate the homing of Vg9Vd2-T cells to subcutaneous
tumor site, highly purified pamidronate-expanded autologous
Vg9Vd2-T cells were labeled with a lipophilic dye (DiR), and
then injected i.v. into tumor-bearing mice established with
EGFP-expressing EBV-LCL. In vivo imaging showed that DiR-
labeled Vg9Vd2-T cells migrated to the tumor sites from 12 hr
after injection and accumulated to a peak level around the tumor
sites at 72 hr after injection of Vg9Vd2-T cells (Figures 4A and 4B).
Confocal fluorescencemicroscope analysis in tumor sections re-
vealed that Vg9Vd2-T cells infiltrated tumors 12 hr after injection
(Figure 4C). These data demonstrated that Vg9Vd2-T cells can
preferentially migrate to subcutaneous tumor sites in mice.
To determine the mechanisms related to the migration of
Vg9Vd2-T cells, chemokine production in EBV-LCL and chemo-
kine receptor expression in Vg9Vd2-T cells were examined.
EBV-LCL secreted relatively high levels of CCR5 ligands, that
is, macrophage inflammatory protein (MIP)-1a (CCL3), MIP-1b
(CCL4), and RANTES (CCL5), but only little or no other
chemokines (monocyte chemotactic protein 1, interleukin-8,
granulocyte-colony-stimulating factor, monokine induced by
gamma-interferon, and interferon gamma-induced protein 10;
Figure 4D). Most Vg9Vd2-T cells expressed CCR5 (Figure 4E).
The migration induced by supernatant from EBV-LCL was abro-
gated by CCR5 neutralizing antibody in a transwell chemotaxis
assay (Figure 4F). In vivo imaging further showed that the migra-
tion of Vg9Vd2-T cells to tumor sites was significantly prevented
when the CCR5was blocked by its neutralizing antibody (Figures
4E, 4G, and 4H). These results demonstrated that the migration
of Vg9Vd2-T cells to tumor sites was mainly mediated by CCR5
and its ligands.
Pamidronate Controls the Development of EBV-LPD in
Humanized Mice
Previously we had demonstrated that pamidronate could selec-
tively expand human Vg9Vd2-T cells, but had no such effect on
any other cell subset, such as CD4, CD8, B, or NK cells in vitro
and in humanized mice (Tu et al., 2011). We then investigated
whether pamidronate could control EBV-LPD in humanized
mice with stable reconstitution of huPBMC by expanding
Vg9Vd2-T cells in vivo. After inoculation with EBV-LCL (1 3
105/mouse) s.c., humanized mice were injected intraperitoneally
(i.p.) with pamidronate (10 mg/kg body weight) at days 0, 7, 14,
21, and 28 after EBV-LCL inoculation (Figure 5A). PBS-treated
mice were used as controls. Similar to Rag2/gc/ mice,
EBV-LPD with subcutaneous tumors developed in all PBS-
treated humanized mice after EBV-LCL inoculation (Figure 5B).-treated group at autopsy.
r human CD20, LMP1, Ki-67, and in situ hybridization for EBER-1/2 in formalin-
ng in mice treated with PAM-expanded Vg9Vd2-T cells or PBS (E). Scale bar
he survival (F), tumor incidence (G), and tumor volume (mean ±SEM) at autopsy
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Figure 3. Vg9Vd2-T Cells Induce the
Regression of EBV-LPD in Tumor-Bearing
Rag2–/–gc–/– Mice
(A) Protocol for evaluation of the therapeutic effect
of Vg9Vd2-T cells EBV-LPD in tumor-bearing
Rag2/gc/ mice. EGFP+ EBV-LCL were inoc-
ulated into Rag2/gc/ mice s.c.. Twenty-one
days later, half of these tumor-bearing mice were
adoptively transferred with the PAM-expanded
autologous Vg9Vd2-T cells i.v. at the indicated
time and another half of these mice were treated
with PBS as the control.
(B) Whole body fluorescence images in mice
before treatment with Vg9Vd2-T cells or PBS.
(C and D) After treatment with Vg9Vd2-T cells
(n = 6) or PBS (n = 6), the tumor volume (C) and
survival (D) in tumor-bearing Rag2/gc/mice
were measured at the indicated time. Data are
mean ± SEM.
(E) Macroscopic appearance of the tumors in
Vg9Vd2-T cell and PBS treated mice at autopsy.
(F) Representative histological analysis and im-
munohistological staining for Ki-67 in formalin-
fixed paraffin-embedded sections from tumors
in mice treated with PAM-expanded Vg9Vd2-T
cells or PBS. Scale bar represents 100 mm. ns, no
significant difference. *p < 0.05.
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EBER-1/2 (Figure 5C). As in Rag2/gc/mice, tumor metasta-
ses were found in liver, kidney, and lung in humanized mice
(Figure 5D). Due to EBV-LPD, all humanized mice died within
100 days of observation (Figure 5E).570 Cancer Cell 26, 565–576, October 13, 2014 ª2014 Elsevier Inc.Treatment with pamidronate signifi-
cantly increased the frequency of
Vg9Vd2-T cells in the peripheral blood,
and the cells could persist for up to
98 days in EBV-LCL-grafted humanized
mice (Figure S3). Pamidronate treatment
also significantly prolonged the sur-
vival of humanized mice (Figure 5E). In
the pamidronate treatment group, only
one out of eight (12.5%) mice died
and three of eight mice (37.5%) had
subcutaneous tumor growth within
100 days. Importantly, humanized mice
receiving pamidronate treatment had
significantly lower tumor incidence and
reduced tumor volume, compared with
PBS-treated humanized mice (Figures
5F and 5G). At day 100, the surviving
seven mice were killed and full nec-
ropsies failed to show any evidence
of tumor metastasis in other organs
(Figure 5D). Histological and immuno-
phenotypic analysis of the residual
tumors showed that the B cell lym-
phomas had fewer Ki67-positive cells
in mice receiving Vg9Vd2-T cells than
that in PBS-treated mice (Figure 5H),indicating the residual tumor cells in Vg9Vd2-T cell-treated
mice had lower proliferative capacity than that in PBS-
treated mice. These data demonstrated that pamidronate
can effectively control the development of EBV-LPD in human-
ized mice.
Figure 4. Homing Program of Vg9Vd2-T Cells in Tumor-Bearing Rag2–/–gc–/– Mice
(A and B) DiR-labeled PAM-expanded Vg9Vd22-T cells were adoptively transferred into Rag2/gc/ mice with subcutaneous tumors after EGFP+ EBV-LCL
inoculation. Themigration and accumulation of Vg9Vd2-T cells (DiR-labeled, red) in the tumor sites (EGFP+, green) weremonitored at indicated time after injection
(A). The fluorescence intensity of DiR signal was measured in the indicated area with dashed lines (B). Data are means ± SEM.
(C) Infiltrated Vg9Vd2-T cells (red) within tumor tissues at 12 hr after adoptive transfer of Vg9Vd2-T cells analyzed with a confocal fluorescencemicroscope. Scale
bar represents 100 mm.
(D) The concentrations of chemokines (means ± SEM) in the supernatants from EBV-LCL were measured (n = 4).
(E) The surface expression of CCR5 on Vg9Vd2-T cells after treatment with anti-CCR5 blocking antibody (aCCR5) or its isotype control (mouse IgG2a, mIgG2a) for
2 hr is shown.
(F) Vg9Vd2-T cells were preincubated with aCCR5, or mIgG2a for 30min and placed in the upper well. The supernatants from EBV-LCL were added into the lower
well. The percentages of cells (means ± SEM) that have migrated from the upper well after 4 hr are shown (n = 4).
(G and H) DiR-labeled PAM-expanded Vg9Vd2-T cells were pretreated with aCCR5 or mIgG2a for 2 hr, and then adoptively transferred into EGFP+ EBV-LCL
subcutaneous tumor-bearing mice. The migration and accumulation of Vg9Vd2-T cells (DiR-labeled, red) in the tumor sites (EGFP+, green) were detected at 24 hr
after injection (G). The fluorescence intensity of DiR signal wasmeasured in the indicated area with dashed lines (H). Data are means ± SEM. Data represent three
to four independent experiments. ns, no significant difference; ND, undetectable. *p < 0.05; **p < 0.01.
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Mice without Vg9Vd2-T Cells
To further determine whether the control of EBV-LPD by pamidr-
onate was mediated through Vg9Vd2-T cells in humanized mice,
mice reconstituted with Vg9Vd2-T cell-depleted huPBMC were
used (Tu et al., 2011). Mice reconstituted with whole huPBMC
or Vg9Vd2-T cell-depleted huPBMC were inoculated with EBV-CLCL s.c. and injected with pamidronate (10 mg/kg body weight)
i.p. at days 0, 7, 14, 21, and 28 after EBV-LCL inoculation. Treat-
ment with pamidronate significantly prolonged survival (Fig-
ure 6A), reduced tumor occurrence (Figure 6B), and decreased
tumor volume (Figure 6C) in humanized mice with whole
huPBMC. In contrast, pamidronate had no such effects in
humanized mice reconstituted with Vg9Vd2-T cell-depletedancer Cell 26, 565–576, October 13, 2014 ª2014 Elsevier Inc. 571
Figure 5. Pamidronate Controls the Development of EBV-LPD in Humanized Mice
(A) Protocol for the control of EBV-LPDby pamidronate (PAM) in humanizedmice. Humanizedmicewere treatedwith PAMor PBS at days 0, 7, 14, 21, and 28 after
inoculation of EBV-LCL.
(B) Typical appearance of subcutaneous tumor in humanized mice from PBS-treated group at autopsy.
(C, D, and H) Representative histological analysis and immunohistological staining for human CD20, LMP1, and Ki-67, and in situ hybridization for EBER-1/2 in
formalin-fixed paraffin-embedded sections from a tumor (C and H) and liver, kidney, and lung in humanized mice treated with PAM or PBS (D). Scale bar rep-
resents 100 mm.
(E–G) After treatment with PAM (n = 8) or PBS (n = 7), the survival (E), tumor incidence (F), and tumor volume (G) were measured at the indicated time. Data are
means ± SEM. *p < 0.05.
See also Figure S3.
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Figure 6. Pamidronate Cannot Control EBV-LPD in Humanized Mice without Vg9Vd2-T Cells
(A–C) Vg9Vd2-T cell-depleted huPBMCwere obtained after double depletions of Vd2-T cells by positive selection with magnetic microbeads. Rag2/gc/mice
were transplanted with whole huPBMC or Vg9Vd2-T cell-depleted huPBMC from the same healthy human donor. In contrast to the mice reconstituted with whole
huPBMC, there were scanty or no human Vg9Vd2-T cells in the mice reconstituted with Vg9Vd2-T cell-depleted huPBMC. Humanized mice reconstituted with
whole huPBMC (PBMC) or Vg9Vd2-T cell-depleted huPBMC (PBMC-gd-T) were inoculated with EBV-LCL and treated with pamidronate or PBS according to the
protocol showed in Figure 5A. The survival (A), tumor incidence (B), and tumor volume (C) in humanized mice (PBMC + PAM, n = 12; PBMC-gd-T + PAM, n = 7;
PBMC-gd-T + PBS, n = 6) are shown. Data are means ± SEM. ns, not significant. *p < 0.05.
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LPD in humanized mice by pamidronate is mainly mediated by
a Vg9Vd2-T cell-dependent mechanism.
DISCUSSION
Immunodeficient mice are widely used as a preclinical model
of EBV studies because lethal human EBV-LPD can develop
rapidly in thesemice inoculated with human EBV-LCL, with char-
acteristics similar to those arising in immunocompromised
humans (Funakoshi et al., 1994; Lacerda et al., 1996). By inocu-
lation of human EBV-LCL in immunodeficient Rag2/gc/
mice, we established lethal EBV-LPD in these mice. Using this
model, we demonstrated that adoptive transfer of pamidro-
nate-expanded human Vg9Vd2-T cells alone not only effectively
prevented EBV-LPD in Rag2/gc/ mice, but also induced
the regression of EBV-LPD in EBV-induced tumor-bearing
Rag2/gc/ mice. The lack of a human immune system in
Rag2/gc/ mice hampers assessment of the pathogenesis,
prevention, and treatment of EBV-LPD, but this can be circum-
vented by reconstitution with huPBMC or CD34+ stem cells
(Lim et al., 2007; Ma et al., 2011). Recently we had established
humanized mice with functional human immune system by
reconstitution of huPBMC in Rag2/gc/ mice (Tu et al.,
2011; Zheng et al., 2013b). These humanized mice contain func-
tional human T and B cells, including a similar percentage
of Vg9Vd2-T cells in peripheral blood as seen in humans (Tu
et al., 2011; Zheng et al., 2013b). In this study, we further induced
lethal EBV-LPD in these humanized mice by inoculation of
human EBV-LCL and showed in this model that pamidronate
treatment inhibited development of EBV-LPD through selective
activation and expansion of Vg9Vd2-T cells in vivo.
Although it has been showed that human gd-T cells have anti-
viral and antitumor activities (Bonneville et al., 2010; Kabelitz
et al., 2007), data supporting their reactivity toward EBV are still
scarce (Kong et al., 2009; Kotsiopriftis et al., 2005). Whereas one
study described in vitro recognition of EBV-LCL by Vd1+ gd-T cell
clones (Orsini et al., 1994), EBV-LCL are classically used asCnegative controls in in vitro cytotoxicity assays using Vg9Vd2-T
cells. Accordingly, we confirmed the lack of EBV-LCL killing by
pamidronate-expanded Vg9Vd2-T cells sorted by negative se-
lection but unexpectedly unveiled significant cytotoxicity against
EBV-LCL by the same cell subset after positive sorting using
anti-TCR monoclonal antibodies (mAb). This suggests that
recently activated Vg9Vd2-T cells can trigger the cytotoxic activ-
ity against EBV-LCL soon after TCR engagement. Our results
further indicate that this process requires cell-cell contact and in-
volves engagement of NKG2D on Vg9Vd2-T cells with MICA/B
expressed on EBV-LCL. Indeed, we also found that the immobi-
lizedMICA/B enhanced Vg9Vd2-T cell activation, granule exocy-
tosis, and cytotoxic activity. Importantly, upon the immobilized
MICA/B stimulation, the levels of the granule exocytosis and
cytotoxicity of Vg9Vd2-T cells sorted by negative selection
were much lower than those in the same cells after positive sort-
ing using anti-TCR mAb. Therefore, both TCR-g/d and NKG2D
are required for the recognition of Vg9Vd2-T cells and TCR-g/d
engagement is essential for triggering their cytotoxic activity
against EBV-LCL.
In line with our previous results using influenza virus-infected
cells (Qin et al., 2009), we also found that the cytotoxic activity
of Vg9Vd2-T cells against EBV-LCL involved engagement
of the death-inducing Fas receptor and release of cytotoxic
effector molecules, such as perforin and granzyme. We further
demonstrated that interaction of another death-inducing re-
ceptor DR5 expressed by EBV-LCL with TRAIL expressed on
Vg9Vd2-T cells also enhanced Vg9Vd2-T cell-mediated EBV-
LCL killing. Importantly, these pamidronate-expanded Vg9Vd2-
T cells couldmigrate to tumor site and infiltrate into tumor tissues
in vivo, thus contributing to the control of EBV-LPD in mice.
Consistent with our previous findings in chemotaxis assay
using influenza virus-infected cells (Qin et al., 2011), using both
transwell chemotaxis and in vivo imaging assays, here we further
showed that the migration of Vg9Vd2-T cells to tumor sites was
mainly mediated by CCR5 and its ligands. Taken together, our
results indicate that pamidronate-expanded Vg9Vd2-T cells
can control EBV-LPD by killing EBV-LCL.ancer Cell 26, 565–576, October 13, 2014 ª2014 Elsevier Inc. 573
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Vg9Vd2-T cells can produce a large amount of interferon gamma
(IFN-g; Qin et al., 2011). One study also demonstrated that IFN-g
secreted from NK cells can delay latent EBV antigen expression,
thus resulting in decreased EBV-induced B cell proliferation
(Strowig et al., 2008). We also found the decreased proliferative
capacity of tumor cells in Vg9Vd2-T cell- and pamidronate-
treated mice, compared with that in control mice. Therefore,
besides their direct killing, Vg9Vd2-T cells might also contribute
to the prevention of the metastases by inhibiting the proliferation
of EBV-LCL through their secreted IFN-g.
We and others previously showed pamidronate-induced
expansion of Vg9Vd2-T cells, but not other T cell subsets, both
in vitro and in humanized mice (Das et al., 2001; Kunzmann
et al., 1999; Sicard et al., 2005; Tu et al., 2011). Although non-
Vg9Vd2 gd T cells could be also activated by pamidronate,
the frequencies of CD69+, perforin+, and granzyme B+ cells in
non-Vg9Vd2 gd T cells were significantly lower than those in
Vg9Vd2-T cells (Tu et al., 2011). Indeed, our adoptive transfer
experiments in Rag2/gc/ mice further showed that pamidr-
onate-expanded Vg9Vd2-T cells readily controlled EBV-LPD
in vivo without help from other human and murine T, B, and NK
cells, which are absent in Rag2/gc/ mice. Importantly, pa-
midronate effectively controlled the development of EBV-LPD
in humanized mice reconstituted with whole huPBMC, but had
no such beneficial effects in mice reconstituted with Vg9Vd2-T
cell-depleted huPBMC. In addition, pamidronate did not show
any cytotoxic activity against EBV-LCL. Therefore, this indicates
that control of EBV-LPD by pamidronate in humanized mice is
mainly mediated by Vg9Vd2-T cells.
As in humans, Vg9Vd2-T cells make up a small percentage of
lymphocytes in humanized mice (Tu et al., 2011). The antitumor
activity of Vg9Vd2-T cells depends on both Vg9Vd2-T cell fre-
quency and degree of activation (Bonneville and Scotet, 2006).
Therefore, we could not observe a difference in disease severity
between mice reconstituted with whole huPBMC and Vg9Vd2-T
cell-depleted huPBMC. Indeed, our in vitro results also showed
that EBV-LCL alone could not efficiently expand Vg9Vd2-T cells
in EBV-seropositive donors. It was only in the presence of
pamidronate that Vg9Vd2-T cells could be expanded and also
induced to express sufficient levels of EBV-LCL recognition
receptors as well as cytotoxic molecules to control the growth
of EBV-LCL.
By contrast with results of adoptive transfer of EBV-specific
CTL that lead to durable eradications of the tumors (Kanakry
and Ambinder, 2013; Khanna et al., 1999; Leen et al., 2007;
Rooney et al., 1995), we showed in some mice that Vg9Vd2-T
cell-based therapy could not completely eradicate the primary
tumors. The variations in frequency and activation of Vg9Vd2-T
cells in different mice might account for this. Thus, it is important
to adjust the dose of pamidronate in real-time according to
results by monitoring the therapeutic effects and frequency of
Vg9Vd2-T cells. Nevertheless, the strategy proposed in this
study by using pamidronate to control EBV-LPD through boost-
ing Vg9Vd2-T cell immunity in vivo has an obvious advantage
because it may avoid the complicated procedures for generation
of EBV-specific CTL in vitro.
In summary, our study demonstrated that pamidronate-
expanded Vg9Vd2-T cells can directly kill the EBV-LCL in vitro574 Cancer Cell 26, 565–576, October 13, 2014 ª2014 Elsevier Inc.and in vivo, and pamidronate can control EBV-LPD in humanized
mice through a Vg9Vd2-T cell dependent mechanism. Our study
provides a strong preclinical proof of principle for a therapeutic
approach using pamidronate to boost human Vg9Vd2-T cell
immunity against EBV-LPD. Pamidronate is commonly used
clinically for the treatment of osteoporosis and Paget disease,
and the use of a human equivalent dose of pamidronate can
effectively control EBV-LPD in humanized mice, suggesting
rapid translation to human clinical trials. This ‘‘new application
of an old drug’’ potentially offers a safe and readily available
option for the treatment of EBV-LPD.
EXPERIMENTAL PROCEDURES
Establishment of EBV-LCL In Vitro
huPBMC were isolated from buffy coats of EBV-seropositive health donors
after informed consents were obtained. The research protocol was approved
by the Institutional Review Board of the University of Hong Kong/Hospital
Authority Hong Kong West Cluster. EBV-LCL were established as described
before (Lacerda et al., 1996). Briefly, huPBMCwere infected with supernatants
from the EBV-secreting cell line B95-8 or B95.8EBfaV-GFP, carrying
an enhanced green fluorescent protein (EGFP, kindly provided by Diane Hay-
ward, Johns Hopkins University, Baltimore; Speck and Longnecker, 1999),
and then cultured in the RPMI 1640 supplemented with 15% heat-inactivated
fetal bovine serum (FBS).
Expansion and Purification of Vg9Vd2-T Cells In Vitro
Pamidronate-expanded Vg9Vd2-T cells were generated as described before
(Tu et al., 2011). Briefly, huPBMCwere cultured in RPMI 1640 medium supple-
mented with 10% FBS. Pamidronate was added at day 0 and day 3 to a final
concentration 9 mg/ml. Recombinant human interleukin-2 (Invitrogen) was
added to a final concentration of 500 UI/ml every third day from day 3. After
14 days of culture, the Vg9Vd2-T cells were purified by positive selection or
negative selection with anti-TCRg/d MicroBead or TCRg/d+ T cell isolation
kit (Miltenyi Biotec). The purity of Vg9Vd2-T cells, as determined with flow
cytometry with anti-CD3 and anti-Vd2 mAbs, was consistently >97%.
Establishment of EBV-LPD Model and Treatment of EBV-LPD
in Humanized and Rag2–/–gc–/– Mice
All animal studies were approved and performed in compliance with the guide-
lines for the use of experimental animals by the Committee on the Use of Live
Animals in the Teaching and Research, the University of Hong Kong. Human-
ized mice were generated in 4- to 5-week-old male or female Rag2/gc/
mice by reconstitution of EBV seropositive whole huPBMC or Vg9Vd2-T cell-
depleted huPBMC as we described before (Tu et al., 2011). After 4 weeks
of huPBMC transplantation, mice were successfully engrafted and became
stable with functional human immune system (Tu et al., 2011), and then
used for establishment of EBV-LPD. Humanized mice or 6- to 8-week-old
Rag2/gc/ mice were inoculated s.c. with EBV-LCL or EGFP-expressing
EBV-LCL (0.13 106/mouse). For Rag2/gc/mice, pamidronate-expanded
autologous Vg9Vd2-T cells (103 106/mouse) in 200 ml of PBS were adoptively
transferred i.v. into mice after inoculation with EBV-LCLs at indicated time. For
humanized mice, a human equivalent dose of PAM (10 mg/kg body weight;
Pamisol; Hospira NZ) was injected i.p. at indicated time. The mice treated
with an equivalent volume of PBS were used as controls. The signs of disease
(loss of activity, weight loss, ruffled hair, palpable tumors, and ascites) and
survival of mice were monitored. Mice with more than 17 mm diameter sub-
cutaneous tumor were killed and counted as dying. Otherwise, mice were
followed for 100 or 170 days and then killed. All mice were examined for
postmortem evidence of tumor. The tumors and organs were collected for
histology and immunohistochemistry assays.
In Vivo Tracking with DiR-Labeled Vg9Vd2-T Cells
Vg9Vd2-T cells were stained with DiR (Invitrogen), and then these DiR-labeled
cells were adoptively transferred intravenously into subcutaneous EGFP-EBV
tumor-bearing mice. The migration and accumulation of Vg9Vd2-T cells were
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the indicated time. After 12 hr, some mice were killed, and tumor sections
were snap-frozen and stained with anti-human TCR g/d mAb (5 mg/ml; B-1,
Biolegend). These cryostat sections were analyzed with a Confocal Laser
Scanning Microscope (LSM 700, Carl Zeiss).
Chemotaxis Assay
The in vitro migration of purified Vg9Vd2-T cells was assessed in a transwell
system (24-well; pore size, 5.0 mm; polycarbonate membranes; Corning-
Costar) as we described before (Qin et al., 2011). Briefly, supernatants from
EBV-LCL after 24 hr of culture in RPMI 1640 medium were collected, and
loaded in the lower compartment. A total of 100 ml of autologous Vg9Vd2-T
cells (4 3 105) in serum-free RPMI 1640 medium was added to the upper
compartment of the chamber. After 4 hr, the cells that had migrated through
the membrane to the lower compartment were collected and counted by
flow cytometry with counting beads. Themigration of Vg9Vd2-T cells in control
group (gd-T cells alone) was set to 100% and the results obtained from other
treatment group or isotype control group were expressed as a percentage of
the control. In blocking experiments, Vg9Vd2-T cells were preincubated for
30 min with either anti-CCR5 mAb (20 mg/ml; clone 2D7, BD) or isotype control
mouse IgG2a (20 mg/ml) mAb.
Cytotoxic Assay
The death of EBV-LCL (target) was analyzed with flow cytometry after 4–6 hr
of coculture with autologous Vg9Vd2-T cells (effector) at different E:T ratios.
In some experiments, a transwell system (24 wells; pore size, 0.4 um; Corn-
ing-Costar) was used to separate Vg9Vd2-T cells from EBV-LCL as we did
before (Qin et al., 2009). In some experiments, neutralization antibodies anti-
NKG2D (10 mg/ml; 149810, R&D System), anti-Fas-L (10 mg/ml; NOK-1, Bio-
legend), anti-TRAIL (10 mg/ml; RIK-2, Biolegend), and isotype control mouse
IgG1 (10 mg/ml) were used for blocking NKG2D-, FasL-, and TRAIL-mediated
pathways (Qin et al., 2009). For MICA/B immobilization, 24-well plates were
coated with recombinant MICA/B proteins (Sino Biological) overnight. The
plates were carefully washed to remove the unbound protein and then incu-
bated with Vg9Vd2-T cells for 6 hr. For blocking perforin and granzyme B,
the perforin inhibitor concanamycin A (1 mg/ml; Sigma) and the granzyme B
inactivator Bcl-2 (1 mg/ml; R&D Systems) were used as we did before (Qin
et al., 2009). Cytotoxicity was analyzed with flow cytometry and calculated
as the percentage of inhibition relative to that in controls. Cells were stained
with anti-CD3 to identify Vg9Vd2-T cells and propidium iodide (PI) was used
to identify dead cells. The death of EBV-LCL was shown as the percentage
of PI+ cells in the CD3 population (Qin et al., 2009).
Histopathology and Immunohistochemistry
Samples of tumors and organs to be analyzed were fixed in 10% formalin,
embedded in paraffin, sectioned, and stained with hematoxylin and eosin.
To investigate the presence of EBV, tissues were stained with mouse anti-
EBV LMP1 (ab58938, Abcam) and the presence of human B cells in tissues
was assessed using rabbit anti-human CD20 (EP459Y, Abcam) with immuno-
peroxidase techniques. The proliferative rate of cells and the aggressive nature
of lymphomas were indicated by histological staining of Ki67 (ab136912,
Abcam). Demonstration of immunostaining was performed with a diaminoben-
zidine detection kit (DAB-0031, Maixin) and the sections were counterstained
with hematoxylin.
In Situ Hybridization
In situ hybridization of paraffin sections from tumors and mouse organs to
detect EB-encoded small RNAs type 1 and 2 (EBER-1/2) was performed using
a DIG-HRP REMBRANDT EBER ISH kit (Tzartos et al., 2012; A500K.9901,
Panpath) according to the manufacturer’s protocol.
Flow Cytometric Analysis
Cells were stained for surface markers with the following antibodies: anti-CD3
(HIT3a), anti-TCR Vd2 (B6), anti-CD69 (FN50), anti-NKG2D (1D11), anti-Fas
(DX2), anti-CD107a (H4A3), anti-FasL (NOK-1), anti-TRAIL (RIK-2), anti-
MICA/B (6D4), anti-DR4 (DJR1), anti-DR5 (DJR2-4), and anti-CCR5 (2D7).
For the intracellular staining, cells were fixed, permeabilized, and then stained
with anti-perforin (dG9) and anti-granzyme B (GB11) antibodies (BD) or theirCrelevant isotype controls as described previously (Qin et al., 2009; Tu et al.,
2011). All samples were acquired with a FACSLSR II (BD) and analyzed with
FlowJo software (Tree Star).
Flowcytomix Assay
The concentrations of chemokines in the supernatants from EBV-LCL culture
were detected and analyzed with human chemokine assay kits (Bender Med-
Systems) as described before (Zheng et al., 2013b).
Statistical Analysis
Data are expressed as means ± SEM. The difference in cell death and viral
copy for in vitro experiments and intensity of florescence, tumor incidence,
and tumor size between PBS and treatment groups were analyzed with
impaired two-tailed Student’s t test. The p value of difference for survival
was determined with Kaplan-Meier log-rank test; p < 0.05 was considered
to be significant.
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